Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
ANN ARBOR, Mich., Feb. 16, 2016 -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C, today announced Tim M. Mayleben, president and chief executive officer, will present at the RBC Capital Markets Global Healthcare Conference in New York City on Tuesday, February 23, 2016 at 3:35 P.M. Eastern Time.
Esperion's Commitment to Cardiometabolic Disease
Esperion is committed to improving the lives of patients by developing therapies to lower elevated LDL-C. Esperion scientists discovered bempedoic acid and the LDL-C lowering therapy is in late stage development. Esperion plans to develop both bempedoic acid and a fixed-dose combination of bempedoic acid and ezetimibe with a particular focus on patients with elevated LDL-C who are considered intolerant of statin therapy. It is estimated that approximately 10% of patients who are prescribed statins, 3.5 million patients in the U.S., are considered statin intolerant
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-C lowering therapies for the treatment of patients with elevated LDL-C. Bempedoic acid, the Company’s lead product candidate, is an inhibitor of ATP Citrate Lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway. Bempedoic acid inhibits cholesterol synthesis, decreases intracellular cholesterol, up-regulates LDL-receptors, and causes increased LDL-C clearance and reduced plasma levels of LDL-C. For more information, please visit www.esperion.com and follow us on Twitter at https://twitter.com/EsperionInc.
Media Contact: Elliot Fox W2O Group 212.257.6724 [email protected] Investor Contact: Mindy Lowe Esperion Therapeutics 734.887.3903 [email protected]
